Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Ribociclib, a CDK4/6 Inhibitor, Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)

NCT02607124 is registered in ClinicalTrials.gov with Children's Hospital Medical Center, Cincinnati as lead sponsor.

NCT NCT02607124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02607124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Ribociclib, a CDK4/6 Inhibitor, Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Phase
Phase 1/2
Overall status
Terminated
Start date
April 30, 2016
Completion date
August 31, 2018
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bithalamic high grade glioma, diffuse intrinsic pontine glioma, high grade glioma